Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Roche | Contract Pharma

What are you searching for?

Sign in
Financial News

Financial Report: Roche

Newly launched medicines Tecentriq, Hemlibra, Ocrevus, Perjeta and Kadcyla offset the impact of competition from biosimilars for established medicines.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Roche
FY Revenues: 58.3 billion CHF (-5%)
FY Earnings 15.1 billion CHF (+7%)
Pharmaceuticals sales were down 2% for the year. Newly launched medicines had continued sales growth (+32%), including Tecentriq, Hemlibra, Ocrevus, Perjeta and Kadcyla, offsetting the impact of competition from biosimilars for the established medicines Herceptin, Avastin and MabThera/Rituxan, with an estimated combined CHF 5.1 billion of sales decline in the U.S, Europe and Japan. The COVID-19 pandemic had an overall negative impact on pharmaceutical sales in 2020, especially for medicines where regular visits to health practices or hospitals are needed. This was partly compensated by additional sales of Actemra/RoActemra (+32%) mostly due to treatment of patients with severe COVID-19-associated pneumonia.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters